MRI-1867 is a peripherally restricted, investigational small-molecule drug that acts as a dual-target inhibitor, functioning as a cannabinoid receptor 1 inverse agonist and an inducible nitric oxide synthase… Read more
MRI-1867 is a peripherally restricted, investigational small-molecule drug that acts as a dual-target inhibitor, functioning as a cannabinoid receptor 1 inverse agonist and an inducible nitric oxide synthase inhibitor. Currently in preclinical development, this compound is studied for its potential therapeutic effects in managing fibrotic and metabolic diseases while minimizing central nervous system side effects. Laboratories researching this agent rely on high-quality reference standards to ensure the accuracy of their analytical workflows. This category provides MRI-1867 and its stable isotope labelled analogue, MRI-1867-d5, which are essential for rigorous impurity profiling, quantitative analysis, and metabolite identification. By utilizing these deuterated compounds as internal standards, researchers can effectively perform method validation and stability testing, ensuring reliable data generation throughout the drug development process.